Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Analysts at Barclays Reconfirmed their Overweight rating for Bluebirdbio (BLUE). The Target Price Given is $209.0

Barclays Capital Analyst Rating Change Bluebirdbio BLUE

Bluebirdbio (BLUE) Rating Maintained

In analysts note revealed on Wednesday, 13 December, Bluebirdbio (BLUE) Stock Overweight was reconfirmed by Barclays. They currently have a $209.0 TP on the stock. Barclays’s TP means a potential upside of 50.25 % from the company’s current price.

BLUE is at the moment trading 0.00% lower at $0.00 as of 8:17 AM New York time. Bluebirdbio’s stock is 0% in the last 200 days. It has underperformed the S&P500, which has risen 6.00% in the same time.

According to data compiled by Thomson Reuters, Bluebirdbio (BLUE)’s stock is covered by 14 equity analysts across the Street, with 0 analysts giving it a Sell rating, 12 a Buy rating, while 3 consider it a Hold. The 12-month consensus target price for the stock is $89.07, which reflects an upside potential of ∞% over the current price.

BLUE Stock Chart

Institutional Ownership

Eventide Asset Management Llc had the largest stake with ownership of 539,500 shares as of q2 2015 for 2.23% of the US long equity exposure. First Light Asset Management Llc is another very bullish fund who is possessing 67,545 shares of Bluebirdbio or 1.97% of their US long equity exposure. In addition, Rtw Investments Llc have 1.8% of their US long equity exposure invested in the company for 87,734 shares. The Pennsylvania-based fund Emerald Advisers Inc Pa disclosed it had bought so far a stake worth about 1.13% of the fund’s stock portfolio in Bluebirdbio. The Pennsylvania-based fund Emerald Mutual Fund Advisers Trust is also positive about the stock, possessing 373,554 shares or 1.12% of their US long equity exposure.

Bluebirdbio (BLUE) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Bluebirdbio has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.

Get the latest Bluebirdbio (BLUE) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Analysts at Barclays Reconfirmed their Overweight rating for Bluebirdbio (BLUE). The Target Price Given is $209.0 appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Analysts at Barclays Reconfirmed their Overweight rating for Bluebirdbio (BLUE). The Target Price Given is $209.0

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×